Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 4Neoplasm Metastasis 3Colorectal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Fanconi Anemia 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Brain Neoplasms 1Anus Neoplasms 1Advanced Cancer 1

Interventions

senaparib 7pembrolizumab 7Irinotecan 6Paclitaxel 5Docetaxel 5Cisplatin 5Capecitabine 5Nivolumab 4Fluorouracil 4Bevacizumab 4Rifampin 3Midazolam 3Leucovorin 3Itraconazole 3Injections 3pertuzumab 2ontuxizumab 2navoximod 2atezolizumab 2Gemcitabine 2vofatamab 1tremelimumab 1trastuzumab duocarmazine 1talazoparib 1sotorasib 1sintilimab 1saracatinib 1rucaparib 1ridaforolimus 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumor × prexasertib × Clear all
NCT03057145 2021-09-02

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
29 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡